397 related articles for article (PubMed ID: 22859495)
1. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts.
Kanda M; Knight S; Topazian M; Syngal S; Farrell J; Lee J; Kamel I; Lennon AM; Borges M; Young A; Fujiwara S; Seike J; Eshleman J; Hruban RH; Canto MI; Goggins M
Gut; 2013 Jul; 62(7):1024-33. PubMed ID: 22859495
[TBL] [Abstract][Full Text] [Related]
2. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
3. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
[TBL] [Abstract][Full Text] [Related]
4. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
[TBL] [Abstract][Full Text] [Related]
5. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
6. McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation - a case report.
Gaujoux S; Pasmant E; Silve C; Mehsen-Cetre N; Coriat R; Rouquette A; Douset B; Prat F; Leroy K
Medicine (Baltimore); 2019 Dec; 98(50):e18102. PubMed ID: 31852070
[TBL] [Abstract][Full Text] [Related]
7. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
[TBL] [Abstract][Full Text] [Related]
9. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
11. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
12. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
Wu J; Matthaei H; Maitra A; Dal Molin M; Wood LD; Eshleman JR; Goggins M; Canto MI; Schulick RD; Edil BH; Wolfgang CL; Klein AP; Diaz LA; Allen PJ; Schmidt CM; Kinzler KW; Papadopoulos N; Hruban RH; Vogelstein B
Sci Transl Med; 2011 Jul; 3(92):92ra66. PubMed ID: 21775669
[TBL] [Abstract][Full Text] [Related]
13. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.
Eshleman JR; Norris AL; Sadakari Y; Debeljak M; Borges M; Harrington C; Lin E; Brant A; Barkley T; Almario JA; Topazian M; Farrell J; Syngal S; Lee JH; Yu J; Hruban RH; Kanda M; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2015 May; 13(5):963-9.e4. PubMed ID: 25481712
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
[TBL] [Abstract][Full Text] [Related]
17. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
[TBL] [Abstract][Full Text] [Related]
18. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
[TBL] [Abstract][Full Text] [Related]
19. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.
Frampton AE; Stebbing J; Gall TM; Silver B; Jiao LR; Krell J
Expert Rev Mol Diagn; 2015 Mar; 15(3):325-8. PubMed ID: 25656048
[TBL] [Abstract][Full Text] [Related]
20. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
